Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01MH074356-03
Application #
7551790
Study Section
Special Emphasis Panel (ZMH1)
Project Start
2007-09-01
Project End
2010-08-31
Budget Start
2007-09-01
Budget End
2008-08-31
Support Year
3
Fiscal Year
2007
Total Cost
$825,031
Indirect Cost

  Institution

Name
Nathan Kline Institute for Psychiatric Research
Department
Type
DUNS #
167204762
City
Orangeburg
State
NY
Country
United States
Zip Code
10962

  Publications

Kantrowitz, Joshua T; Epstein, Michael L; Lee, Migyung et al. (2018) Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms. Schizophr Res 191:70-79
Kantrowitz, Joshua T; Woods, Scott W; Petkova, Eva et al. (2015) D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial. Lancet Psychiatry 2:403-412
Woods, Scott W; Walsh, Barbara C; Hawkins, Keith A et al. (2013) Glycine treatment of the risk syndrome for psychosis: report of two pilot studies. Eur Neuropsychopharmacol 23:931-40
Javitt, Daniel C (2012) Glycine transport inhibitors in the treatment of schizophrenia. Handb Exp Pharmacol :367-99
Cornblatt, Barbara A; Carrión, Ricardo E; Addington, Jean et al. (2012) Risk factors for psychosis: impaired social and role functioning. Schizophr Bull 38:1247-57
Seidman, Larry J; Giuliano, Anthony J; Meyer, Eric C et al. (2010) Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis. Arch Gen Psychiatry 67:578-88
Kantrowitz, Joshua T; Malhotra, Anil K; Cornblatt, Barbara et al. (2010) High dose D-serine in the treatment of schizophrenia. Schizophr Res 121:125-30
Javitt, Daniel C (2009) Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification. Curr Opin Drug Discov Devel 12:468-78